2025
Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy MAPLE-HCM Rationale, Study Design, and Baseline Characteristics
Garcia-Pavia P, Bilen O, Burroughs M, Costabel J, de Barros Correia E, Dybro A, Elliott P, Lakdawala N, Mann A, Nair A, Nassif M, Poulsen S, Reant P, Schulze P, Wang A, Berhane I, Heitner S, Jacoby D, Kupfer S, Malik F, Meng L, Sohn R, Wohltman A, Fifer M, Investigators M. Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy MAPLE-HCM Rationale, Study Design, and Baseline Characteristics. JACC Heart Failure 2025, 13: 346-357. PMID: 39909646, DOI: 10.1016/j.jchf.2024.11.011.Peer-Reviewed Original ResearchConceptsObstructive hypertrophic cardiomyopathyStandard-of-careCardiac myosin inhibitorStandard-of-care medicationsBaseline characteristicsSymptomatic obstructive hypertrophic cardiomyopathyNondihydropyridine calcium channel blockersBaseline characteristics of patientsStandard-of-care drugsSecond-line therapyFirst-line therapyCalcium channel blockersCharacteristics of patientsImprove exercise capacityMyosin inhibitorFirst-lineBeta-blockersHypertrophic cardiomyopathyExercise capacityAlleviate symptomsPatientsAficamtenMedicationTherapyStudy design
2024
Are Cardiac Myosin Inhibitors Useful in Patients With Hypertrophic Obstructive Cardiomyopathy and Comorbid Hypertension? ∗
Sikand N, Sen S. Are Cardiac Myosin Inhibitors Useful in Patients With Hypertrophic Obstructive Cardiomyopathy and Comorbid Hypertension? ∗. JACC Heart Failure 2024, 12: 580-582. PMID: 38448152, DOI: 10.1016/j.jchf.2023.12.021.Commentaries, Editorials and Letters
2023
Baseline and Longitudinal Imaging of Hypertrophic Cardiomyopathy in the Era of Emerging Therapeutics
Altibi A, Alani A, Zhao Y, Masri A. Baseline and Longitudinal Imaging of Hypertrophic Cardiomyopathy in the Era of Emerging Therapeutics. Current Cardiology Reports 2023, 25: 583-595. PMID: 37103749, DOI: 10.1007/s11886-023-01883-w.Peer-Reviewed Original ResearchConceptsCardiac myosin inhibitorCardiac magnetic resonance imagingHypertrophic cardiomyopathyCare of patientsClinical trialsPathophysiology of hypertrophic cardiomyopathyCardiac magnetic resonanceNew drug therapiesHypertrophic cardiomyopathy diagnosisActin-myosin cross-bridgesLongitudinal imagingMagnetic resonance imagingMyosin inhibitorTherapeutic optionsAbstract PurposeDrug therapyOral moleculesLongitudinal imaging modalityCardiomyopathyPatientsMonitoring PatientsImaging modalitiesResonance imagingInvestigate new drug therapiesSarcomere level
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply